Structure Therapeutics (GPCR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.24
- Surprise
- —
- Score today
- 5.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference — fiscal.ai, 2026-11-04
Where TrendMatrix's rating stands now
TrendMatrix currently rates GPCR Sell at 5.0/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Pipeline: aleniglipron
- DATA_ISSUE: analyst_target_implausible (raw $107.29 vs price $20.35 — ratio 5.3×). Rejected, falling back to technical TP.
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.35
- Price target
- $24.99
- Stop
- $18.93
- Upside to target
- +22.8%
Risk check: trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
GPCR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.45B
- P/E (fwd)
- -9.6
- 52-week range
- $18.70–$94.90
- Off 52-week high
- 78.6%
- RSI (14)
- 39
- Volume vs avg
- 1.50×
- Score today
- 5.0/10